Abstract 2783
Background
Individual Care plans should be a co-creation between the patient and the health care provider, and should be updated by the contact nurse (CN) that is the patients’ main point of contact. Until recently the individual care plans for patients with Head & Neck cancer (H&N) in our region constituted of extensive written information in a ring binder and in addition a treatment plan from the medical records were printed and given to the patient. This quality improvement project aims to implement a digital and interactive version of the care plan, with a greater possibility to tailor information and increased availability. The implementation process contained of both the introduction of the digital tool (the care plan) and also new work processes for the nurses.
Methods
We followed the Plan Do Study Act approach. A clinical nurse leader together with the designer of the and an IT-technician worked together with the preparations (education, testing and risk assessment). All patients with H&N cancer could choose a standard care plan or the new digital format. The digital care plan was prepared by the CN. A person-centered approach was adopted for the digital care plans, with mandatory questions at the first visit with the CN; “What is important to you? - What is important that I know about you?”.
Results
30 % of chose the digital version of the individual care plan (n = 45) (patients were asked to choose either printed or digital). Patients and nurses were asked to give feedback on the content, usefulness and to suggest improvements. The first evaluation from the patients suggests improved patient participation and satisfaction. The CN stated that the digital care plan had advantages such as less time consuming, improved communication with the patients and supporting person-centered care. The patients can interact with the CN and may also use different symptom assessment scales and were involved during the whole implementation phase.
Conclusions
There is a potential for increased use of screening tools and systematic assessment of symptoms with the digital version of the IWCP. The mandatory question gave important information to the CN to consider. A designated nurse leader involved in the process is important during the implementation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Regional Cancer Center Stockholm Gotland.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract